Pioneering method of treating Alzheimer’s discredited by scientists
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession
A drug hailed as a pioneering method of treating Alzheimer’s has been discredited by scientists, after experts were unable to replicate its results this week.
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession, following high profile research that suggested it could be used to treat the symptoms of Alzheimer’s.
The 2012 research, produced by Gary Landreth and colleagues at Case Western Reserve University in Cleveland and published in Science journal, reported that the drug appeared to reduce the brain plaque build-ups linked to the disease when administered to mice.
Once the results of the study were made public, patients began requesting the drug and some doctors reportedly began prescribing it.
However, a team of experts have now written in the same journal that they have been unable to re-create the results found in the original survey, plunging its validity into doubt.
Sangram Sisodia, professor of neuroscience at the University of Chicago, decided to investigate claims made that the drug could reduce the areas of plaque by 50 per cent within three days, and by 75 per cent in two weeks.
In his replica study published on Thursday, he said: “In view of the significant implications of these landmark findings for the development of novel AD therapeutics, we performed a small pilot study […] using 8-month-old male APP/PS1 mice that were treated orally with a commercial source of bexarotene for seven days.”
Crucially, he said: “We failed to observe any differences in hippocampal or cortical amyloid plaque area or plaque counts between vehicle and bexarotene-treated animals.”
Bexarotene was approved by the FDA in 1999 as a treatment for skin cancer, but has never before been tested as a treatment for humans with Alzheimer’s. Because it has been approved by the FDA it can be prescribed by physicians for use ‘off label.’
However, some scientists argued that whilst the effects on brain plaque had not been replicated, the cognitive improvements had.
Writing in Science, Professor Koldamova said: “We believe these findings make a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer's disease.”
- 1 Rihanna 'nude pictures' claims emerge on 4Chan as hacking scandal continues
- 2 Kim Kardashian 'nude photos' leaked on 4chan weeks after Jennifer Lawrence scandal
- 3 'F*ck it, I quit': KTVA reporter Charlo Greene quits live on air in spectacular fashion
- 4 Free U2 album: How the most generous giveaway in music history turned PR disaster
- 5 Scotland could still declare independence – even without referendum, says Alex Salmond
Rihanna 'nude pictures' claims emerge on 4Chan as hacking scandal continues
Tesco in crisis: UK managing director among four executives suspended after exposure of accounting scandal
Kim Kardashian 'nude photos' leaked on 4chan weeks after Jennifer Lawrence scandal
'F*ck it, I quit': KTVA reporter Charlo Greene quits live on air in spectacular fashion
Alicia Keys leaks own nude photo 'to create a kinder and more peaceful world'
Scotland could still declare independence – even without referendum, says Alex Salmond
Scottish referendum results: Cross-party consensus collapses amid Tory-Labour spat on the 'English question'
Hilary Mantel 'should be investigated by police' over Margaret Thatcher assassination story, says Lord Bell
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
Plebgate MP Andrew Mitchell called officer a 'little s**t', claim court documents 'exposing ex-Chief Whip's 'record of abusing police'
Archbishop of Canterbury admits doubts about existence of God
£11280 - £14400 per annum: Randstad Education Manchester Secondary: Teaching a...
£21552 - £31588 per annum: Randstad Education Cambridge: Randstad Education re...
£21000 - £35000 per annum: Randstad Education Cambridge: Science teachers requ...
£30000 - £35000 per annum: Sauce Recruitment: A successful, Central London bas...